Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.47 |
| ▸ | STAT3 | P40763 | 3/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 3/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23915135 | 0.92 | CRBN (0.46) | HDAC1HDAC2HDAC3NCOR2STAT3 | |
| SCHEMBL24745278 | 0.88 | STAT3 (0.49) | HDAC1HDAC2HDAC3NCOR2STAT3 | |
| SCHEMBL22511915 | 0.86 | STAT3 (0.47) | HDAC1HDAC2HDAC3NCOR2STAT3 | |
| SCHEMBL23945868 | 0.85 | CRBN (0.48) | HDAC1HDAC2HDAC3NCOR2STAT3 | |
| SCHEMBL25102496 | 0.85 | HDAC1 (0.47) | HDAC1HDAC2HDAC3NCOR2STAT3 | |
| SCHEMBL23915711 | 0.85 | CRBN (0.47) | HDAC1HDAC2HDAC3NCOR2STAT3 | |
| SCHEMBL21106385 | 0.84 | CRBN (0.39) | HDAC1HDAC2HDAC3NCOR2CRBN | |
| SCHEMBL21307518 | 0.84 | CRBN (0.63) | HDAC1HDAC2HDAC3NCOR2STAT3 | |
| SCHEMBL23915176 | 0.83 | CRBN (0.46) | HDAC1HDAC2HDAC3NCOR2STAT3 | |
| SCHEMBL23915611 | 0.83 | CRBN (0.53) | HDAC1HDAC2HDAC3NCOR2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | HIPK1, MCL1, HYPK | HDAC1 1183/4885HDAC2 1856/4885HDAC3 1077/4885 |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | HDAC1 1716/4885HDAC2 1737/4885HDAC3 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.